vs
Side-by-side financial comparison of Sight Sciences, Inc. (SGHT) and U-BX Technology Ltd. (UBXG). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $12.4M, roughly 1.6× U-BX Technology Ltd.). Sight Sciences, Inc. runs the higher net margin — -20.4% vs -24.7%, a 4.3% gap on every dollar of revenue.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
SGHT vs UBXG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $12.4M |
| Net Profit | $-4.2M | $-3.1M |
| Gross Margin | 87.3% | 0.4% |
| Operating Margin | -18.0% | -22.1% |
| Net Margin | -20.4% | -24.7% |
| Revenue YoY | 6.9% | — |
| Net Profit YoY | 64.9% | — |
| EPS (diluted) | $-0.07 | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | — | ||
| Q3 25 | $19.9M | — | ||
| Q2 25 | $19.6M | $12.4M | ||
| Q1 25 | $17.5M | — | ||
| Q4 24 | $19.1M | — | ||
| Q3 24 | $20.2M | — | ||
| Q2 24 | $21.4M | — | ||
| Q1 24 | $19.3M | — |
| Q4 25 | $-4.2M | — | ||
| Q3 25 | $-8.2M | — | ||
| Q2 25 | $-11.9M | $-3.1M | ||
| Q1 25 | $-14.2M | — | ||
| Q4 24 | $-11.8M | — | ||
| Q3 24 | $-11.1M | — | ||
| Q2 24 | $-12.3M | — | ||
| Q1 24 | $-16.3M | — |
| Q4 25 | 87.3% | — | ||
| Q3 25 | 86.4% | — | ||
| Q2 25 | 84.8% | 0.4% | ||
| Q1 25 | 86.2% | — | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | 83.9% | — | ||
| Q2 24 | 85.8% | — | ||
| Q1 24 | 85.5% | — |
| Q4 25 | -18.0% | — | ||
| Q3 25 | -39.7% | — | ||
| Q2 25 | -59.6% | -22.1% | ||
| Q1 25 | -79.2% | — | ||
| Q4 24 | -62.5% | — | ||
| Q3 24 | -55.7% | — | ||
| Q2 24 | -59.2% | — | ||
| Q1 24 | -76.4% | — |
| Q4 25 | -20.4% | — | ||
| Q3 25 | -41.0% | — | ||
| Q2 25 | -61.0% | -24.7% | ||
| Q1 25 | -80.8% | — | ||
| Q4 24 | -62.1% | — | ||
| Q3 24 | -54.9% | — | ||
| Q2 24 | -57.7% | — | ||
| Q1 24 | -84.4% | — |
| Q4 25 | $-0.07 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.23 | $-0.55 | ||
| Q1 25 | $-0.28 | — | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.25 | — | ||
| Q1 24 | $-0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.0M | — |
| Total DebtLower is stronger | $42.4M | — |
| Stockholders' EquityBook value | $63.9M | $19.0M |
| Total Assets | $115.3M | $21.0M |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.0M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $101.5M | — | ||
| Q1 25 | $108.8M | — | ||
| Q4 24 | $120.4M | — | ||
| Q3 24 | $118.6M | — | ||
| Q2 24 | $118.2M | — | ||
| Q1 24 | $127.3M | — |
| Q4 25 | $42.4M | — | ||
| Q3 25 | $42.4M | — | ||
| Q2 25 | $42.4M | — | ||
| Q1 25 | $42.4M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $37.1M | — | ||
| Q2 24 | $35.0M | — | ||
| Q1 24 | $35.0M | — |
| Q4 25 | $63.9M | — | ||
| Q3 25 | $64.3M | — | ||
| Q2 25 | $70.0M | $19.0M | ||
| Q1 25 | $77.6M | — | ||
| Q4 24 | $87.5M | — | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $101.6M | — | ||
| Q1 24 | $109.2M | — |
| Q4 25 | $115.3M | — | ||
| Q3 25 | $116.3M | — | ||
| Q2 25 | $122.0M | $21.0M | ||
| Q1 25 | $129.7M | — | ||
| Q4 24 | $142.8M | — | ||
| Q3 24 | $143.6M | — | ||
| Q2 24 | $149.7M | — | ||
| Q1 24 | $155.6M | — |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.32× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $-1.2M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -9.7% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-8.7M | — | ||
| Q2 25 | $-7.5M | $-1.2M | ||
| Q1 25 | $-11.6M | — | ||
| Q4 24 | $-3.5M | — | ||
| Q3 24 | $362.0K | — | ||
| Q2 24 | $-9.5M | — | ||
| Q1 24 | $-9.8M | — |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | $-7.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-3.6M | — | ||
| Q3 24 | $311.0K | — | ||
| Q2 24 | $-9.5M | — | ||
| Q1 24 | $-9.9M | — |
| Q4 25 | -9.7% | — | ||
| Q3 25 | -44.7% | — | ||
| Q2 25 | -39.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -18.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | -44.7% | — | ||
| Q1 24 | -51.4% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.6% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
UBXG
Segment breakdown not available.
